C6 gene unlocks mysteries to our immunity
Posted: 2 July 2018 | Drug Target Review | No comments yet
Researchers have identified a new gene that plays a critical role in regulating the body’s immune response to infection and disease…


Researchers have identified a new gene that plays a critical role in regulating the body’s immune response to infection and disease.
The discovery could lead to the development of new treatments for influenza, arthritis and even cancer.
The gene, called C6orf106 or “C6”, controls the production of proteins involved in infectious diseases, cancer and diabetes. The gene has existed for 500 million years, but its potential is only now understood.
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!
“Our immune system produces proteins called cytokines that help fortify the immune system and work to prevent viruses and other pathogens from replicating and causing disease,” CSIRO researcher Dr Cameron Stewart said.
“C6 regulates this process by switching off the production of certain cytokines to stop our immune response from spiralling out of control.
“The cytokines regulated by C6 are implicated in a variety of diseases including cancer, diabetes and inflammatory disorders such as rheumatoid arthritis.”
The discovery helps improve our understanding of our immune system, and it is hoped that this understanding will enable scientists to develop new, more targeted therapies.
“Even though the human genome was first fully sequenced in 2003, there are still thousands of genes that we know very little about,” Dr Rebecca Ambrose, a former CSIRO researcher, now based at the Hudson Institute of Medical Research said.
“It’s exciting to consider that C6 has existed for more than 500 million years, preserved and passed down from simple organisms all the way to humans. But only now are we gaining insights into its importance.”
Having discovered the function of C6, the researchers are awarded the privilege of naming it and are enlisting the help of the community to do so.
“The current name, C6orf106, reflects the gene’s location within the human genome, rather than relating to any particular function,” Dr Stewart said.
“We think we can do better than that, and are inviting suggestions from the public.” A shortlist of names will be made available for final approval by a governing third party.
The breakthrough builds on decades of work in infectious diseases, by researchers from CSIRO, Australia’s national science agency.
The researchers will be announcing the discovery in the Journal of Biological Chemistry.
Related topics
Cytokines, Disease Research, Genomics
Related organisations
Australia's national science agency CSIRO, Hudson Institute of Medical Research
Related people
Dr Cameron Stewart, Dr Rebecca Ambrose